{"id":66491,"date":"2026-05-27T21:28:55","date_gmt":"2026-05-27T13:28:55","guid":{"rendered":"https:\/\/flcube.com\/?p=66491"},"modified":"2026-05-27T21:28:56","modified_gmt":"2026-05-27T13:28:56","slug":"transthera-sciences-and-allist-pharmaceuticals-launch-phase-ii-combination-study-of-tt-00973-and-furmonertinib-in-egfr-mutant-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66491","title":{"rendered":"TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>TransThera Sciences (Nanjing), Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2617:HKG\">HKG: 2617<\/a>) and <strong>Allist Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688578:SHA\">SHA: 688578<\/a>) have announced a strategic partnership to jointly advance a <strong>multicenter, open-label Phase II clinical study<\/strong> evaluating the combination of <strong>TT-00973-MS<\/strong> and <strong>furmonertinib<\/strong> in patients with <strong>locally advanced or metastatic non-small cell lung cancer (NSCLC)<\/strong> harboring <strong>EGFR-sensitive mutations<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-partnership-framework\" class=\"wp-block-heading\">Partnership Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Role<\/th><th>Responsibilities<\/th><th>Asset Contribution<\/th><\/tr><\/thead><tbody><tr><td><strong>TransThera Sciences<\/strong> (HKG: 2617)<\/td><td>Clinical Trial Sponsor<\/td><td>Trial operation, regulatory oversight, and full funding<\/td><td>TT-00973-MS (AXL\/FLT3 dual-target inhibitor)<\/td><\/tr><tr><td><strong>Allist Pharmaceuticals<\/strong> (SHA: 688578)<\/td><td>Drug Supply Partner<\/td><td>Manufacturing and quality control<\/td><td>Furmonertinib (EGFR-TKI) provided free of charge<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-investigational-combination-therapy\" class=\"wp-block-heading\">Investigational Combination Therapy<\/h2>\n\n\n\n<h3 id=\"h-tt-00973-transthera-s-novel-dual-target-inhibitor\" class=\"wp-block-heading\">TT-00973 \u2013 TransThera&#8217;s Novel Dual-Target Inhibitor<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Type:<\/strong> Novel AXL\/FLT3 dual-target inhibitor<\/li>\n\n\n\n<li><strong>Development Status:<\/strong> In-house developed by TransThera Sciences<\/li>\n\n\n\n<li><strong>Mechanism Rationale:<\/strong> AXL inhibition may overcome resistance mechanisms to EGFR-TKIs in NSCLC<\/li>\n\n\n\n<li><strong>Therapeutic Innovation:<\/strong> Dual targeting addresses both primary driver (EGFR) and resistance pathways (AXL)<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-furmonertinib-allist-s-approved-egfr-tki\" class=\"wp-block-heading\">Furmonertinib \u2013 Allist&#8217;s Approved EGFR-TKI<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Type:<\/strong> Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)<\/li>\n\n\n\n<li><strong>Development Status:<\/strong> Developed and commercialized by Allist Pharmaceuticals<\/li>\n\n\n\n<li><strong>Current Indications:<\/strong> Approved for EGFR-mutant NSCLC in China<\/li>\n\n\n\n<li><strong>Combination Rationale:<\/strong> Established efficacy as monotherapy provides foundation for enhanced combination approach<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-study-design\" class=\"wp-block-heading\">Clinical Study Design<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase:<\/strong> Phase II (multicenter, open-label)<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Locally advanced or metastatic NSCLC with EGFR-sensitive mutations<\/li>\n\n\n\n<li><strong>Primary Endpoints:<\/strong> Safety and efficacy assessment of combination therapy<\/li>\n\n\n\n<li><strong>Study Scope:<\/strong> Multiple clinical sites across China<\/li>\n\n\n\n<li><strong>Future Pathway:<\/strong> Positive results to inform Phase III trial design and potential regulatory submissions<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-scientific-basis\" class=\"wp-block-heading\">Strategic Rationale &amp; Scientific Basis<\/h2>\n\n\n\n<h3 id=\"h-overcoming-egfr-tki-resistance\" class=\"wp-block-heading\">Overcoming EGFR-TKI Resistance<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Challenge:<\/strong> Acquired resistance to EGFR-TKIs remains major limitation in NSCLC treatment<\/li>\n\n\n\n<li><strong>AXL Pathway Role:<\/strong> AXL activation identified as key resistance mechanism to EGFR inhibition<\/li>\n\n\n\n<li><strong>Dual-Target Approach:<\/strong> Simultaneous inhibition of EGFR and AXL may delay or prevent resistance development<\/li>\n\n\n\n<li><strong>FLT3 Component:<\/strong> Additional FLT3 inhibition may provide broader anti-tumor activity<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-commercial-synergies\" class=\"wp-block-heading\">Commercial Synergies<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Complementary Portfolios:<\/strong> Combines TransThera&#8217;s novel targeted therapy with Allist&#8217;s established EGFR-TKI<\/li>\n\n\n\n<li><strong>Market Expansion:<\/strong> Potential to extend furmonertinib&#8217;s lifecycle through combination indication<\/li>\n\n\n\n<li><strong>Risk Sharing:<\/strong> Efficient resource allocation with TransThera funding operations and Allist providing drug supply<\/li>\n\n\n\n<li><strong>Regulatory Strategy:<\/strong> Leverages existing furmonertinib approval while developing novel combination regimen<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>EGFR-Mutant NSCLC Market:<\/strong> $8+ billion global market with significant growth in Asia-Pacific region<\/li>\n\n\n\n<li><strong>China Leadership:<\/strong> Both companies represent leading Chinese oncology innovators with domestic regulatory expertise<\/li>\n\n\n\n<li><strong>Combination Therapy Trend:<\/strong> Industry shift toward rational combinations to address resistance mechanisms<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Differentiates from other EGFR-TKI combinations through novel AXL\/FLT3 dual inhibition<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-development-timeline-amp-next-steps\" class=\"wp-block-heading\">Development Timeline &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current Status:<\/strong> Phase II study initiation underway<\/li>\n\n\n\n<li><strong>Data Readouts:<\/strong> Expected 2027-2028 timeframe<\/li>\n\n\n\n<li><strong>Phase III Planning:<\/strong> Joint evaluation of Phase II results to determine Phase III trial feasibility<\/li>\n\n\n\n<li><strong>Partnership Evolution:<\/strong> Framework established for potential expanded collaboration beyond initial study<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, partnership outcomes, and market expectations for the TT-00973\/furmonertinib combination. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and partnership execution challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026052601841_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026052601841_c.\"><\/object><a id=\"wp-block-file--media-1890c800-52dd-4c7b-bccb-c15cb8be85de\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026052601841_c.pdf\">2026052601841_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026052601841_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-1890c800-52dd-4c7b-bccb-c15cb8be85de\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TransThera Sciences (Nanjing), Inc. (HKG: 2617) and Allist Pharmaceuticals Co., Ltd. (SHA: 688578) have announced&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[138,4181,922,33,601],"class_list":["post-66491","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","category-drug","tag-allist-pharmaceuticals","tag-hkg-2617","tag-sha-688578","tag-tkis-egfr-vegf-btk-etc","tag-transthera-sciences"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"TransThera Sciences (Nanjing), Inc. (HKG: 2617) and Allist Pharmaceuticals Co., Ltd. (SHA: 688578) have announced a strategic partnership to jointly advance a multicenter, open-label Phase II clinical study evaluating the combination of TT-00973-MS and furmonertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR-sensitive mutations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66491\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC\" \/>\n<meta property=\"og:description\" content=\"TransThera Sciences (Nanjing), Inc. (HKG: 2617) and Allist Pharmaceuticals Co., Ltd. (SHA: 688578) have announced a strategic partnership to jointly advance a multicenter, open-label Phase II clinical study evaluating the combination of TT-00973-MS and furmonertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR-sensitive mutations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66491\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-27T13:28:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-27T13:28:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66491#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66491\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC\",\"datePublished\":\"2026-05-27T13:28:55+00:00\",\"dateModified\":\"2026-05-27T13:28:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66491\"},\"wordCount\":499,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Allist Pharmaceuticals\",\"HKG: 2617\",\"SHA: 688578\",\"TKIs (EGFR VEGF BTK etc.)\",\"TransThera Sciences\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66491#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66491\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66491\",\"name\":\"TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-27T13:28:55+00:00\",\"dateModified\":\"2026-05-27T13:28:56+00:00\",\"description\":\"TransThera Sciences (Nanjing), Inc. (HKG: 2617) and Allist Pharmaceuticals Co., Ltd. (SHA: 688578) have announced a strategic partnership to jointly advance a multicenter, open-label Phase II clinical study evaluating the combination of TT-00973-MS and furmonertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR-sensitive mutations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66491#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66491\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66491#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC - Insight, China&#039;s Pharmaceutical Industry","description":"TransThera Sciences (Nanjing), Inc. (HKG: 2617) and Allist Pharmaceuticals Co., Ltd. (SHA: 688578) have announced a strategic partnership to jointly advance a multicenter, open-label Phase II clinical study evaluating the combination of TT-00973-MS and furmonertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR-sensitive mutations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66491","og_locale":"en_US","og_type":"article","og_title":"TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC","og_description":"TransThera Sciences (Nanjing), Inc. (HKG: 2617) and Allist Pharmaceuticals Co., Ltd. (SHA: 688578) have announced a strategic partnership to jointly advance a multicenter, open-label Phase II clinical study evaluating the combination of TT-00973-MS and furmonertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR-sensitive mutations.","og_url":"https:\/\/flcube.com\/?p=66491","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-27T13:28:55+00:00","article_modified_time":"2026-05-27T13:28:56+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66491#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66491"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC","datePublished":"2026-05-27T13:28:55+00:00","dateModified":"2026-05-27T13:28:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66491"},"wordCount":499,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Allist Pharmaceuticals","HKG: 2617","SHA: 688578","TKIs (EGFR VEGF BTK etc.)","TransThera Sciences"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66491#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66491","url":"https:\/\/flcube.com\/?p=66491","name":"TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-27T13:28:55+00:00","dateModified":"2026-05-27T13:28:56+00:00","description":"TransThera Sciences (Nanjing), Inc. (HKG: 2617) and Allist Pharmaceuticals Co., Ltd. (SHA: 688578) have announced a strategic partnership to jointly advance a multicenter, open-label Phase II clinical study evaluating the combination of TT-00973-MS and furmonertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR-sensitive mutations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66491#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66491"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66491#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66491","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66491"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66491\/revisions"}],"predecessor-version":[{"id":66493,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66491\/revisions\/66493"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66491"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66491"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66491"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}